Crucell N.V. and GlaxoSmithKline Biologicals have signed an agreement to collaborate on the development of a second-generation malaria vaccine candidate. Preclinical data from earlier studies indicated significantly enhanced immune responses against the malaria parasite when Crucell’s Adenovirus (AdVac) technology and GSK’s RTS,S/AS technology are used in combination, versus either component alone. Crucell will contribute its recombinant malaria vaccine candidate, Ad35-CS, based o...